We serve Chemical Name:Boron trifluoride-methanol CAS:373-57-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Boron trifluoride-methanol
CAS.NO:373-57-9
Synonyms:Methanol, compd. with trifluoroborane (1:1);Boron trifluoride;Boron Trifluoride Methanol;Boron trifluoride-methanol;Trifluoroborane;EINECS 206-766-4;Methanol – trifluoroborane (1:1);Trifluoro(methanol)boron;MFCD00071635
Molecular Formula:CH4BF3O
Molecular Weight:99.848
HS Code:28129019
Physical and Chemical Properties:
Melting point:N/A
Boiling point:59ºC (4 mmHg)
Density:1.203
Index of Refraction:n20/D 1.328
PSA:20.23000
Exact Mass:100.030731
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2924
Packing Group:I
Contact us for information like Methanol, compd. with trifluoroborane (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00071635 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Boron trifluoride-methanol Use and application,Boron trifluoride technical grade,usp/ep/jp grade.
Related News: The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. 2-Bromo-5-chloro-1-benzothiophene manufacturers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. (+)-isopinocampheol suppliers but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. 2-Bromo-1-(2-hydroxy-5-methylphenyl)ethanone vendor & factory The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.,The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually.